INZY logo

Inozyme Pharma, Inc. Common Stock


INZY: Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.


Show INZY Financials

Consumer Interest
SEC Filings

Recent trades of INZY by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by INZY's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods of treating tissue calcification May. 16, 2023
  • Patent Title: Methods of treating myointimal proliferation Jun. 21, 2022
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of INZY in WallStreetBets Daily Discussion


Recent insights relating to INZY

CNBC Recommendations

Recent picks made for INZY stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in INZY

Corporate Flights

Flights by private jets registered to INZY